Patents by Inventor James Strong
James Strong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8066985Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: GrantFiled: November 25, 2008Date of Patent: November 29, 2011Assignee: Oncolytics Biotech Inc.Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
-
Publication number: 20110216463Abstract: A line protection system described herein provides reliable electro-mechanical connections between system components, reduces mechanical stresses on a disconnector, assures more effective disconnection of a failed arrestor, and is lower in cost than existing systems. The line protection system includes a surge arrestor, a disconnector coupled to the surge arrestor, and a line lead coupled to the disconnector. The line lead generally is a high strength cable and/or the line protection system generally does not include a shunt bypass assembly. Upon exposure to a high voltage condition, the disconnector actuates and separates the line lead from the system.Type: ApplicationFiled: March 8, 2011Publication date: September 8, 2011Inventors: Jeffrey J. Kester, Charles W. Daley, James A. Strong
-
Publication number: 20110014155Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: ApplicationFiled: July 22, 2010Publication date: January 20, 2011Applicant: ONCOLYTICS BIOTECH INC.Inventors: Patrick W.K. Lee, James Strong, Matthew C. Coffey
-
Patent number: 7675728Abstract: A housing encapsulating first and second terminals of a surge arrester disconnector becomes structurally weakened before activation of a disconnect device in the disconnector when the disconnector is exposed to heat, thereby preventing the disconnector from producing a projectile with a force sufficient to classify the disconnector as a hazardous material under Department of Transportation regulations.Type: GrantFiled: October 26, 2007Date of Patent: March 9, 2010Assignee: Cooper Technologies CompanyInventors: Jonathan Jay Woodworth, James A. Strong, David R. Miller
-
Publication number: 20090117082Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: ApplicationFiled: November 25, 2008Publication date: May 7, 2009Applicant: ONCOLYTICS BIOTECH INC.Inventors: Patrick W.K. Lee, James Strong, Matthew C. Coffey
-
Publication number: 20090109592Abstract: A housing encapsulating first and second terminals of a surge arrester disconnector becomes structurally weakened before activation of a disconnect device in the disconnector when the disconnector is exposed to heat, thereby preventing the disconnector from producing a projectile with a force sufficient to classify the disconnector as a hazardous material under Department of Transportation regulations.Type: ApplicationFiled: October 26, 2007Publication date: April 30, 2009Applicant: Cooper Technologies CompanyInventors: Jonathan Jay Woodworth, James A. Strong, David R. Miller
-
Publication number: 20090110665Abstract: Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: ApplicationFiled: November 3, 2008Publication date: April 30, 2009Applicant: ONCOLYTICS BIOTECH INC.Inventors: Patrick W.K. Lee, James Strong, Matthew C. Coffey
-
Publication number: 20090098089Abstract: Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: ApplicationFiled: October 16, 2008Publication date: April 16, 2009Applicant: ONCOLYTICS BIOTECH INC.Inventors: Patrick W.K. Lee, James Strong, Matthew C. Coffey
-
Patent number: 7476382Abstract: Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: GrantFiled: April 30, 2004Date of Patent: January 13, 2009Assignee: Oncolytics Biotech Inc.Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
-
Patent number: 7374752Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: GrantFiled: August 11, 2004Date of Patent: May 20, 2008Assignee: Oncolytics Biotech Inc.Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
-
Publication number: 20080026048Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: ApplicationFiled: May 30, 2007Publication date: January 31, 2008Applicant: Oncolytics Biotech Inc.Inventors: Patrick Lee, James Strong, Matthew Coffey
-
Patent number: 7300650Abstract: Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, and use of reovirus for manufacture of a medicament for the treatment of neoplasia, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other sterotypes or strains of reovirus can be used. Combinations of more than one type and/or strain or reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: GrantFiled: April 1, 2003Date of Patent: November 27, 2007Assignee: Oncolytics Biotech Inc.Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
-
Publication number: 20060164781Abstract: An electrical apparatus of an electric distribution power system includes an electrical device having a high voltage electrical terminal that may be energized, an exterior insulating housing, and an insulator. The exterior insulating housing surrounds and insulates the electrical device, and includes an opening through which the high voltage electrical terminal protrudes such that at least a portion of the high voltage electrical terminal is external to the exterior insulating housing. The insulator covers the electrical terminal and is attached to the exterior insulating housing such that no current flow path is provided through an interface between the insulator and the exterior insulating housing.Type: ApplicationFiled: January 25, 2006Publication date: July 27, 2006Inventors: James Strong, David Miller, Jonathan Woodworth
-
Publication number: 20060129058Abstract: A system for receiving at least one electromyogram signal representing physiological activity in a quadruped. The system may comprise a first probe and a wireless receiver in wireless communication with the first probe. Also, an electromyogram device for determining a neuromuscular balance of a quadruped. The device may comprise a first probe and a second probe. The device may also comprise a processor in communication with the first probe and the second probe. The processor may be configured to compare a first electromyogram signal captured from the first probe and a second electromyogram signal captured from the second probe. Additional embodiments include an electrode for receiving an electromyogram signal representing physiological activity in a quadruped and a method for analyzing the physiology of a quadruped.Type: ApplicationFiled: December 13, 2004Publication date: June 15, 2006Inventors: James Strong, George Power, Errin Miller
-
Publication number: 20050123513Abstract: Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: ApplicationFiled: April 30, 2004Publication date: June 9, 2005Inventors: Patrick Lee, James Strong, Matthew Coffey
-
Publication number: 20050063954Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: ApplicationFiled: August 11, 2004Publication date: March 24, 2005Applicant: Oncolytics Biotech Inc., a Canada corporationInventors: Patrick Lee, James Strong, Matthew Coffey
-
Publication number: 20040265271Abstract: Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, and use of reovirus for manufacture of a medicament for the treatment of neoplasia, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other sterotypes or strains of reovirus can be used. Combinations of more than one type and/or strain or reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: ApplicationFiled: April 1, 2003Publication date: December 30, 2004Applicant: Oncolytics Biotech Inc.Inventors: Patrick W.K. Lee, James Strong, Matthew C. Coffey
-
Patent number: 6811775Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: GrantFiled: August 15, 2002Date of Patent: November 2, 2004Assignee: Oncolytics Biotech Inc.Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
-
Patent number: 6576234Abstract: Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, and use of reovirus for manufacture of a medicament for the treatment of neoplasia, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other sterotypes or strains of reovirus can be used. Combinations of more than one type and/or strain or reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: GrantFiled: May 10, 2001Date of Patent: June 10, 2003Assignee: Oncolytics Biotech Inc.Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
-
Publication number: 20030003080Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.Type: ApplicationFiled: August 15, 2002Publication date: January 2, 2003Inventors: Patrick W.K. Lee, James Strong, Matthew C. Coffey